166 related articles for article (PubMed ID: 37194068)
1. Live birth rates following individualized dosing algorithm of follitropin delta in a long GnRH agonist protocol.
Sánchez MF; Larsson P; Serrano MF; Bosch E; Velasco JAG; López ES; Mannaerts B
Reprod Biol Endocrinol; 2023 May; 21(1):45. PubMed ID: 37194068
[TBL] [Abstract][Full Text] [Related]
2. A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol.
Fernández Sánchez M; Višnová H; Larsson P; Yding Andersen C; Filicori M; Blockeel C; Pinborg A; Khalaf Y; Mannaerts B;
Hum Reprod; 2022 May; 37(6):1161-1174. PubMed ID: 35451013
[TBL] [Abstract][Full Text] [Related]
3. Comparative clinical outcome following individualized follitropin delta dosing in Chinese women undergoing ovarian stimulation for in vitro fertilization /intracytoplasmic sperm injection.
Yang R; Zhang Y; Liang X; Song X; Wei Z; Liu J; Yang Y; Tan J; Zhang Q; Sun Y; Wang W; Qian W; Jin L; Wang S; Xu Y; Yang J; Goethberg M; Mannaerts B; Wu W; Zheng Z; Qiao J
Reprod Biol Endocrinol; 2022 Oct; 20(1):147. PubMed ID: 36195924
[TBL] [Abstract][Full Text] [Related]
4. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients.
Qiao J; Zhang Y; Liang X; Ho T; Huang HY; Kim SH; Goethberg M; Mannaerts B; Arce JC
Hum Reprod; 2021 Aug; 36(9):2452-2462. PubMed ID: 34179971
[TBL] [Abstract][Full Text] [Related]
5. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
[TBL] [Abstract][Full Text] [Related]
6. Cumulative live birth rates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols.
Toftager M; Bogstad J; Løssl K; Prætorius L; Zedeler A; Bryndorf T; Nilas L; Pinborg A
Hum Reprod; 2017 Mar; 32(3):556-567. PubMed ID: 28130435
[TBL] [Abstract][Full Text] [Related]
7. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial.
Ishihara O; Arce JC;
Reprod Biomed Online; 2021 May; 42(5):909-918. PubMed ID: 33722477
[TBL] [Abstract][Full Text] [Related]
8. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial.
Nyboe Andersen A; Nelson SM; Fauser BC; García-Velasco JA; Klein BM; Arce JC;
Fertil Steril; 2017 Feb; 107(2):387-396.e4. PubMed ID: 27912901
[TBL] [Abstract][Full Text] [Related]
9. Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis.
van Tilborg TC; Oudshoorn SC; Eijkemans MJC; Mochtar MH; van Golde RJT; Hoek A; Kuchenbecker WKH; Fleischer K; de Bruin JP; Groen H; van Wely M; Lambalk CB; Laven JSE; Mol BWJ; Broekmans FJM; Torrance HL;
Hum Reprod; 2017 Dec; 32(12):2485-2495. PubMed ID: 29121350
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of potential high responders after individualized FSH dosing based on anti-Müllerian hormone and body weight.
Višnová H; Papaleo E; Martin FS; Koziol K; Klein BM; Mannaerts B
Reprod Biomed Online; 2021 Dec; 43(6):1019-1026. PubMed ID: 34756645
[TBL] [Abstract][Full Text] [Related]
11. The depot GnRH agonist protocol improves the live birth rate per fresh embryo transfer cycle, but not the cumulative live birth rate in normal responders: a randomized controlled trial and molecular mechanism study.
Xu B; Geerts D; Hu S; Yue J; Li Z; Zhu G; Jin L
Hum Reprod; 2020 Jun; 35(6):1306-1318. PubMed ID: 32478400
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of follitropin delta for ovarian stimulation in vitro fertilization/ intracytoplasmic sperm injection cycles: a systematic review with meta-analysis.
Palomba S; Caserta D; Levi-Setti PE; Busnelli A
J Ovarian Res; 2024 Mar; 17(1):60. PubMed ID: 38486276
[TBL] [Abstract][Full Text] [Related]
13. Prospective multicenter non-interventional real-world study to assess the patterns of use, effectiveness and safety of follitropin delta in routine clinical practice (the PROFILE study).
Blockeel C; Griesinger G; Rago R; Larsson P; Sonderegger YLY; Rivière S; Laven JSE
Front Endocrinol (Lausanne); 2022; 13():992677. PubMed ID: 36619578
[TBL] [Abstract][Full Text] [Related]
14. [Cumulative live birth rates per oocytes retrieved cycle: evaluation of clinical outcomes of IVF/ICSI].
Wu CX; Zhang T; Shu L; Huang J; Diao FY; Ding W; Gao Y; Wang W; Mao YD; Cui YG; Liu JY
Zhonghua Fu Chan Ke Za Zhi; 2018 Mar; 53(3):160-166. PubMed ID: 29609229
[No Abstract] [Full Text] [Related]
15. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
Youssef MA; Van der Veen F; Al-Inany HG; Griesinger G; Mochtar MH; Aboulfoutouh I; Khattab SM; van Wely M
Cochrane Database Syst Rev; 2011 Jan; (1):CD008046. PubMed ID: 21249699
[TBL] [Abstract][Full Text] [Related]
16. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
Youssef MA; Van der Veen F; Al-Inany HG; Griesinger G; Mochtar MH; van Wely M
Cochrane Database Syst Rev; 2010 Nov; (11):CD008046. PubMed ID: 21069701
[TBL] [Abstract][Full Text] [Related]
17. Follitropin delta combined with menotropin in patients at risk for poor ovarian response during in vitro fertilization cycles: a prospective controlled clinical study.
Duarte-Filho OB; Miyadahira EH; Matsumoto L; Yamakami LYS; Tomioka RB; Podgaec S
Reprod Biol Endocrinol; 2024 Jan; 22(1):7. PubMed ID: 38166856
[TBL] [Abstract][Full Text] [Related]
18. Individualized ovarian stimulation for in vitro fertilization: a multicenter, open label, exploratory study with a mixed protocol of follitropin delta and highly purified human menopausal gonadotropin.
Bissonnette F; Minano Masip J; Kadoch IJ; Librach C; Sampalis J; Yuzpe A
Fertil Steril; 2021 Apr; 115(4):991-1000. PubMed ID: 33267959
[TBL] [Abstract][Full Text] [Related]
19. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: The predicted hyper responder.
Oudshoorn SC; van Tilborg TC; Eijkemans MJC; Oosterhuis GJE; Friederich J; van Hooff MHA; van Santbrink EJP; Brinkhuis EA; Smeenk JMJ; Kwee J; de Koning CH; Groen H; Lambalk CB; Mol BWJ; Broekmans FJM; Torrance HL;
Hum Reprod; 2017 Dec; 32(12):2506-2514. PubMed ID: 29121269
[TBL] [Abstract][Full Text] [Related]
20. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology.
Al-Inany HG; Youssef MA; Ayeleke RO; Brown J; Lam WS; Broekmans FJ
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD001750. PubMed ID: 27126581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
